Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

January 14, 2022

Study Completion Date

February 14, 2022

Conditions
Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaMyelodysplastic SyndromeChronic Myelogenous LeukemiaNon-Hodgkin LymphomaHodgkin Lymphoma
Interventions
RADIATION

Radiation

1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days

DRUG

Cyclophosphamide

Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days

BIOLOGICAL

Donor Lymphocyte Infusion (DLI)

DLI containing 1 x 10E8/kg donor T-cells

BIOLOGICAL

Haploidentical Stem Cell Transplantation

2-10 x 10E6/kg donor CD34+ selected cells

Trial Locations (1)

11040

Cohen Children's Medical Center, New Hyde Park

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

New York Blood Center

OTHER

lead

Northwell Health

OTHER